Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.
AIDS
; 38(9): 1355-1365, 2024 07 15.
Article
em En
| MEDLINE
| ID: mdl-38788210
ABSTRACT
OBJECTIVE:
We evaluated the immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV (PWH).DESIGN:
Prospective observational cohort study.METHODS:
PWH aged ≥45âyears received Wuhan-BA.1 mRNA-1273.214 and those <45âyears Wuhan-BA.1 BNT162b2. Participants were propensity score-matched 1ââ2 to people without HIV (non-PWH) by age, primary vaccine platform (mRNA-based or vector-based), number of prior COVID-19 boosters and SARS-CoV-2 infections, and spike (S1)-specific antibodies on the day of booster administration. The primary endpoint was the geometric mean ratio (GMR) of ancestral S1-specific antibodies from day 0 to 28 in PWH compared to non-PWH. Secondary endpoints included humoral responses, T-cell responses and cytokine responses up to 180âdays post-vaccination.RESULTS:
Forty PWH received mRNA-1273.214 ( N â=â35) or BNT162b2 ( N â=â5) following mRNA-based ( N â=â29) or vector-based ( N â=â11) primary vaccination. PWH were predominantly male (87% vs. 26% of non-PWH) and median 57âyears [interquartile range (IQR) 53-59]. Their median CD4 + T-cell count was 775 (IQR 511-965) and the plasma HIV-RNA load was <50âcopies/ml in 39/40. The GMR of S1-specific antibodies by 28âdays post-vaccination was comparable between PWH [4.48, 95% confidence interval (CI) 3.24-6.19] and non-PWH (4.07, 95% CI 3.42-4.83). S1-specific antibody responses were comparable between PWH and non-PWH up to 180âdays, and T-cell responses up to 90âdays post-vaccination. Interferon-γ, interleukin (IL)-2, and IL-4 cytokine concentrations increased 28âdays post-vaccination in PWH.CONCLUSION:
A bivalent BA.1 booster vaccine was immunogenic in well treated PWH, eliciting comparable humoral responses to non-PWH. However, T-cell responses waned faster after 90âdays in PWH compared to non-PWH.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Imunização Secundária
/
Imunogenicidade da Vacina
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
/
Vacina BNT162
/
Anticorpos Antivirais
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
AIDS
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2024
Tipo de documento:
Article